Brief: Biophytis Reports Clinical Results For Sarconeos (BIO101)
19/06/2023 06:09
June 19 (Reuters) - Biophytis SA ALBPS.PA :
* BIOPHYTIS REPORTS CLINICAL RESULTS FOR SARCONEOS (BIO101)
IN
SARCOPENIA TREATMENT AT THE 16TH SCWD INTERNATIONAL CONGRESS
* EMA AND FDA APPROVALS FOR START OF PHASE 3 OF SARA PROGRAM
ARE
EXPECTED IN SECOND HALF OF 2023
* SARCONEOS (BIO101) WOULD THEREFORE BE THE FIRST AND ONLY
DRUG
CANDIDATE TO ENTER PHASE 3 FOR THE TREATMENT OF SARCOPENIA
Source text for Eikon: ID:nEQ9vzXtpa
Further company coverage: ALBPS.PA
(Gdansk Newsroom)
((gdansk.newsroom@thomsonreuters.com; +48 58 7696600;))
Recent news on Biophytis SA
See all newsBrief: Biophytis SA Secures $20 Mln For Launch Of Phase 3 Trial In Sarcopenia
Brief: Biophytis Secures Public Funding In Brazil For Obesity Phase 2 Trial
Brief: Biophytis SA Gets EMA Authorization For Phase 2 Clinical Trial In Obesity
Brief: Biophytis Gets EMA & Belgian Regulatory Approval For Phase 3 Sarcopenia Clinical Trial
Brief: Biophytis To Initiate Phase 2 Study In Obesity & Phase 3 Study In Sarcopenia Soon